A new study has revealed that the use of aspirin for COVID-19, while not necessarily harmful, has shown no clear positive benefits against those who have been hospitalized with the virus. The international study included participants at 177 hospitals in the UK, as well as hospitals in Indonesia and Nepal. The study investigated the impact of 150 mg of aspirin per day in addition to the usual standards of care in the treatment of patients who had tested positive for COVID-19. The nearly five-month study involved more than 22,000 patients. “In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days,” the RECOVERY Collaborative Group study reported. The trial only studied hospitalized patients, however, limiting the evidence. …